GLP-1
Cagrilintide
SaveA long-acting acylated amylin analog developed by Novo Nordisk, designed to reduce appetite and food intake through amylin receptor signaling. Studied as monotherapy and in combination with semaglutide.
Quick verdict
Significant weight loss in Phase II as monotherapy. The combination with semaglutide (CagriSema) is the primary development focus.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Phase II monotherapy data showed up to ~10% weight loss over 26 weeks. The mechanism complements GLP-1 by targeting the amylin pathway. Most development resources are now focused on the CagriSema combination.
Benefits
- Novel amylin-based mechanism distinct from GLP-1
- Meaningful Phase II weight loss as monotherapy
- Complementary to GLP-1 receptor agonism
Dosage notes
Phase II studied 1.2–4.5 mg subcutaneously once weekly.
Side effects
- Nausea
- Vomiting
- Diarrhea
- Injection site reactions
Who should be cautious
Not yet approved. GI side effects are common. Long-term safety data is still being collected.
What this page cannot tell you
Phase II data only. The standalone clinical profile may be less relevant than the combination product.
Leaderboard scores
- Weight loss60
Write a review
Sign in to write a review.